timothy sykes logo
TWST Surges As Twist Bioscience Wins Eli Lilly AI Deal Thumbnail
G Google News

TWST Surges As Twist Bioscience Wins Eli Lilly AI Deal

JACK KELLOGG•UPDATED SEP. 19, 2026, 10:06 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Twist Bioscience Corporation stocks have been trading up by 7.1 percent amid investor optimism over its latest breakthrough developments

What Traders Need To Know

  • Shares of Twist Bioscience Corporation jumped after it agreed to provide antibody characterization data services to Eli Lilly’s AI-driven TuneLab drug discovery platform.
  • The Lilly TuneLab deal integrates Twist Bioscience wet-lab data directly into Lilly’s AI/ML models, tying TWST to the high-profile AI drug discovery theme.
  • Leerink lifted its TWST price target from $120 to $160, keeping an Outperform rating and pointing to conservative revenue forecasts and a large AI opportunity.
  • UBS started coverage on Twist Bioscience Corporation with a Neutral rating but a hefty $144 target, signaling meaningful upside within a life science tools group expected to outgrow global GDP.
  • Management confirmed that AI-designed mini-binder work for Anthropic is real and likely already baked into its 2027 orders view, limiting near-term upside from that project alone.

Candlestick Chart

Weekly Update Sep 14 – Sep 18, 2026: On Saturday, September 19, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 7.1%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Twist Bioscience holds a differentiated position in synthetic biology and antibody services, with revenue of ~$377M growing nearly 10% three-year CAGR but decelerating from a 5‑year ~28% pace. Gross margin at 52% is competitive for tools, yet EBIT margin at -31.8% and ROE near -30% underscore a still-unprofitable model. Cash burn is narrowing but persistent: Q3 FY26 operating cash flow was barely positive ($1.1M) while free cash flow was -$8.6M, and valuation is rich at ~24x sales and ~23x book.

Technically, TWST is in a powerful upside breakout. The weekly tape shows a vertical move from 133.41 to 166.60 in four sessions, with successive higher highs and no meaningful pullback, consistent with heavy upside volume around the Lilly/TuneLab headlines. Intraday five-minute candles show aggressive dip-buying above 155. The actionable level is $155–157: former breakout area and now first support; as long as TWST holds above 155 on a closing basis, the dominant trend remains strongly bullish.

Catalysts are skewed to the upside. The Lilly TuneLab agreement validates Twist’s antibody and data capabilities in AI-driven drug discovery, while commentary on Anthropic mini-binder work and the Leerink PT hike to $160 frame TWST as a key AI-enablement asset in tools, outgrowing typical Healthcare and Diagnostics peers but with materially worse profitability. UBS’s $144 target sets a floor for institutional expectations. Base case: TWST re-tests $160 near term with technical resistance at $175 and support at $155.

More Breaking News

Quick Financial Overview

Twist Bioscience Corporation sits in an interesting spot: strong revenue growth, heavy losses, and a chart that just caught a powerful AI catalyst. The company posted trailing revenue of about $376.6M, with a gross margin of 52%, which tells traders the core product has solid pricing power. However, profit margins are deeply negative, with EBIT margin around -31.8% and net margins similar, so the firm is still very much in “build and scale” mode.

Leverage is manageable, with total debt to equity of 0.21 and a current ratio near 2.7, which gives Twist Bioscience Corporation some room to keep funding growth and volatility in cash flows. The latest quarterly numbers show revenue of $118.4M but a net loss of roughly $35.1M and EBITDA around -$27.96M. Operating cash flow was slightly positive at $1.1M for the quarter, but free cash flow ran about -$8.65M once capital spending is included, reinforcing that TWST trades as a high-multiple, story-driven growth name.

Technically, the weekly data show a strong ramp: from $133.41 to $166.60 over recent sessions, with a key breakout day where TWST opened near $155.40 and closed at $157.20, then pushed toward the high $160s. Intraday, a 5‑minute bar that ran from a $158.04 open to a $166.99 close, with a low near $156.16, signals aggressive buying on the Eli Lilly TuneLab news. For short-term traders, that type of wide intraday range often marks a momentum pivot area, with $156–$158 now acting as a first support zone to watch.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”